1.	Vaccine Therapy in Treating Patients With Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 16 and over Sponsor: Other Protocol IDs: CDR0000068493, HOAG-VACCINE-RN, NCI-V01-1647, NCT00014131
2.	Vaccine Therapy in Treating Patients With Liver Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: CDR0000068806, P30CA016042, UCLA-0001026, NCI-G01-1997, NCT00022334
3.	Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: ERLANGEN-1490, EU-20232, NCT00053391
4.	Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40- Ligand and Denileukin Diftitox in Patients With HLA-A1- and/or HLA-A2.1-Positive Stage III or IV Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: over 18 Sponsor: Other Protocol IDs: ERLANGEN-ONTAK, EU-20246, NCT00056134
5.	Phase I/II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Transfected With Autologous Polymerase Chain Reaction-Amplified Tumor RNA in Patients With Stage IV Cutaneous Melanoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: ERLANGEN-DERMA-ER-DC-07, EU-20513, ARGOS-ERLANGEN-DERMA-DC-07, NCT00126685
6.	Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells. Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: RDA 0466, NCT00289341
7.	Combined Modality Treatment for Patients With Stage IV Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 21 to 75 Sponsor: Other Protocol IDs: Baylor IRB #006-025-01, IND 12919, NCT00313235
8.	Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: RDA-0537, NCT00345293
9.	Dendritic Cell Based Therapy of Renal Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UR0414, NCT00197860
10.	Dendritic Cell Based Therapy of Malignant Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MM0413, NCT00197912
11.	Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection Phase: Phase II, Phase I Type: Diagnostic, Treatment Status: Completed Age: 18 to 75 Sponsor: Other Protocol IDs: 2004-3126, KUN99-1950, NCT00243594
12.	Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CRITICAL001, NCT00753220
13.	Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 20 and over Sponsor: Other Protocol IDs: 198, NCT00795977
14.	A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1 Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 19 and over Sponsor: Other Protocol IDs: CAN-ONC-001 CAN, NCT00852007
15.	Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Phase: Phase II, Phase I Type: Treatment Status: Temporarily closed Age: 19 months to 35 years Sponsor: NCI Protocol IDs: 070206, 07-C-0206, NCT00923351
16.	Toll-like Receptor (TLR) Ligand Matured Dendritic Cell Vaccination in Melanoma Patients Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Other Protocol IDs: NL22750.000.08, KUN2006-3699, NCT00940004
17.	Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 16 Sponsor: Other Protocol IDs: CDR0000068481, HOAG-VACCINE-MEL, NCI-V01-1646, NCT00012064
18.	A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Phase: Phase II Type: Treatment Status: Completed Age: 35 and under at initial diagnosis Sponsor: NCI Protocol IDs: 970052, 97-C-0052, NCI-97-C-0052, NCI-T96-0038, T96-0038, NCT00019266, NCT00001566
19.	Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma Phase: Phase II Type: Treatment Status: Completed Age: 16 and over Sponsor: NCI Protocol IDs: CDR0000067277, NCI-99-C-0132, NCT00019890
20.	p53 Vaccine for Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: 990137, 99-C-0137, NCI-99-C-0137, NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903, NCT00001827
21.	APC8015 and Bevacizumab in Treating Patients With Prostate Cancer Phase: Phase II Type: Treatment Status: Completed Age: Not specified Sponsor: NCI Protocol IDs: NCI-2012-02427, UCSF-0155-01, NCI-2617, UCSF-01554, CDR0000069047, 2617, NCT00027599
22.	DC Vaccine Combined With IL-2 and IFNa-2a in Treating Patients With mRCC Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000370794, R01CA095648, P30CA023108, DMS-0238, DMS-16090, NCT00085436
23.	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2000-46, NCT00083538
24.	Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: Pro00007616, DUMC-5883-04-6RO, CDR000041079, 8087, NCT00103142
25.	Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI, Other Protocol IDs: CDR0000410830, R21CA091624, UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009, NCT00103116